Bangalore:Bioconhas announced that its manufacturing site in Cranbury, New Jersey, has received a single observation following a GMP inspection by the U.S. Food and Drug Administration (USFDA). This inspection took place after the inauguration of the Company’s first manufacturing site in Cranbury in September by its wholly owned subsidiary, Biocon Generics Inc (BGI). Read also:Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion "This is to inform that subsequent to the inauguration of the Company’s first manufacturing site in the United States, located in Cranbury, New Jersey, in September, that will support capacity expansion and supply chain efficiency in the region, the facility underwent a GMP inspection by the U.S. FDA," Biocon stated in a BSE filing. Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. Read also:Biocon Pharma, Carnegie Pharma gain USFDA tentative nod for Rifaximin Tablets to treat irritable bowel syndrome with diarrhea
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!